HBM Holdings Limited (6XY.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jingsong Wang M.D., Ph.D. | Founder, Chairman & CEO | 942.57k | -- | 1965 |
| Dr. Yiping Rong Ph.D. | Chief Scientific Officer & Executive Director | 360.37k | -- | 1978 |
| Mr. Youchen Chen | VP, CFO & Investor Relations | -- | -- | -- |
| Dr. Ian Y. Liu | Senior VP & Global Head of Legal | -- | -- | -- |
| Dr. Peter F. Moesta Ph.D. | Member of Scientific Advisory Board & Chief CMC Advisor | -- | -- | -- |
| Dr. Xiaolu Tao | Chief Development Officer | -- | -- | 1975 |
| Dr. Steve Arkinstall DPhil | Chief Scientific Advisor | -- | -- | -- |
| Dr. Ben Chih Ph.D. | Chief Scientific Officer of Neurosciences - Harbour BioMed US | -- | -- | -- |
| Dr. Raymond S. Zheng Ph.D. | Chief Business Officer | -- | -- | -- |
| Mr. Michael D. Patten | Chief Strategy Officer & Head of Global Alliance | -- | -- | -- |
HBM Holdings Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 183
Description
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel antibody therapeutics in immunology and oncology disease areas. It has developed the Harbour Mice Platform, which generates fully human monoclonal antibodies in the classical two heavy and two light chain H2L2 and heavy chain formats. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; HBM7008, a bispecific antibody targeting tumor Associated antigen; HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4; and HBM1020, human monoclonal antibody generated from harbour mice platform targeting B7H7. The company is also developing HBM9378 for the treatment of Asthma; and HBM1022, HBM9014, HBM7022, HBM9027, HBM7004 and HBM9014 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaborations with AstraZeneca, Pfizer, HBM Alpha Therapeutics, Boostimmune, Alaya.bio, Umoja Biopharma, Alkyon Therapeutics, Inc., OverT Bio, Kodiak Sciences Inc.. HBM Holdings Limited was incorporated in 2016 and is based in Suzhou, the People's Republic of China.
Corporate Governance
Upcoming Events
March 31, 2025 at 10:59 AM UTC
HBM Holdings Limited Earnings Date
Recent Events
Recent Events Information Not Available